A recent phase II study on the efficacy and safety of lebrikizumab as a potential “add-on” therapy to topical corticosteroid (TCS) led to significant improvement over placebo. Lebrikizumab is an IL-13 monoclonal antibody. The study participants took lebrikizumab every 4 weeks combined with the topical corticosteroid.
Read the study at the Journal of the American Academy of Dermatology. (Open Access)
Work Cited:
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE) Simpson, Eric L. et al., Journal of the American Academy of Dermatology, Volume 78, Issue 5, 863-871.e11